002648:SZSESatellite Chemical Co. Ltd. Class A Analysis
Data as of 2026-03-17 - not real-time
CN¥25.99
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Satellite Chemical is trading at CNY 25.99, comfortably above its 20‑day SMA of 24.95 and 50‑day SMA of 22.22, signaling a sustained uptrend. The MACD line sits at 1.53 above the signal line, producing a bullish histogram, while the 14‑day RSI of 55 indicates neither overbought nor oversold conditions. Daily volume has been rising, supporting the price advance, and the technical support sits around 22.10 with resistance near 30.00, giving the stock a clear upside corridor. Market sentiment is in the “Extreme Greed” zone (fear‑greed index 81.5), further fueling buying pressure. Overall, the price action aligns with a bullish technical profile.
Fundamentally, the stock trades at a forward‑PE of 13.96 and a trailing‑PE of 14.94, modest multiples for a specialty chemicals player with a 20.5% ROE and a solid 12.7% profit margin. The dividend yield of 1.85% and a low payout ratio of 27% are underpinned by strong operating cash flow (CNY 11.5 bn) and free cash flow (CNY 9.2 bn). Although revenue fell 12.2% YoY, the company maintains a gross margin of 22.4% and a healthy cash balance of 7.4 bn, offsetting a high debt‑to‑equity ratio of 78%. A discounted cash‑flow model suggests a fair value of CNY 31.93, implying upside potential beyond the current level. Analysts rate the stock as a “strong buy” with a mean target of CNY 25.34, reinforcing the positive outlook.
Fundamentally, the stock trades at a forward‑PE of 13.96 and a trailing‑PE of 14.94, modest multiples for a specialty chemicals player with a 20.5% ROE and a solid 12.7% profit margin. The dividend yield of 1.85% and a low payout ratio of 27% are underpinned by strong operating cash flow (CNY 11.5 bn) and free cash flow (CNY 9.2 bn). Although revenue fell 12.2% YoY, the company maintains a gross margin of 22.4% and a healthy cash balance of 7.4 bn, offsetting a high debt‑to‑equity ratio of 78%. A discounted cash‑flow model suggests a fair value of CNY 31.93, implying upside potential beyond the current level. Analysts rate the stock as a “strong buy” with a mean target of CNY 25.34, reinforcing the positive outlook.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD with positive histogram
- Price above 20‑day and 50‑day SMAs
- Rising trading volume supporting momentum
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value indicating ~20% upside
- Strong ROE and cash flow generation
- Attractive dividend yield with low payout ratio
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Exposure to growth segments like new energy materials
- High debt‑to‑equity ratio requiring monitoring
- Valuation converging toward fair value
Key Metrics & Analysis
Financial Health
Revenue Growth-12.20%
Profit Margin12.74%
P/E Ratio14.9
ROE20.46%
ROA7.35%
Debt/Equity78.41
P/B Ratio2.7
Op. Cash FlowCN¥11.5B
Free Cash FlowCN¥9.2B
Technical Analysis
TrendBullish
RSI55.6
SupportCN¥22.10
ResistanceCN¥30.00
MA 20CN¥24.95
MA 50CN¥22.22
MA 200CN¥19.06
MACDBullish
VolumeIncreasing
Fear & Greed Index81.54
Valuation
Fair ValueCN¥31.93
Target PriceCN¥25.34
Upside/Downside-2.50%
GradeUndervalued
TypeBlend
Dividend Yield1.85%
Risk Assessment
Beta0.19
Volatility68.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.